Während die Konkurrenz das Thema "Nachgeschmack" durch neue Glykoside in den Griff bekommen hat, investierte Sunwin das, eh schon spärlich veranlagte, R&D-Geld lediglich in "consulting fees" für "Third Parties".
"Research and Development Expense
For the three months ended July 31, 2017, our research and development expenses amounted to approximately $186,000, as compared to $39,000 for the same period in 2016. The increase of $147,000 was primarily due to the increase in spendings for third party technical consulting fees in the three months ended July 31, 2017."
www.sec.gov/Archives/edgar/data/806592/...000035/suwn10-q.htm